Navigation Links
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
Date:8/30/2007

WASHINGTON, Aug. 30 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held biotechnology company, today announced that it has hired Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer.

Dr. Stogniew will be responsible for Prestwick's pre-clinical development, regulatory and patent activities around its portfolio of products including its lead product candidate, tetrabenazine, a highly selective and reversible dopamine depletor in Phase 3 clinical trials for potential use as a treatment for chorea associated with Huntington's Disease.

He joins Prestwick most recently from Zelos Therapeutics, where he was Executive Vice President of Development responsible for pre-clinical, regulatory and patent development.

"With 25 years focused on developing drugs and 25 patents to his name, Marty will immediately help Prestwick as we work to execute and enhance our pipeline," said George F. Horner III, President and Chief Executive Officer of Prestwick. "He has made a significant impact in the development of successful drugs such as Anidulafugin, Amifostine and Idarubicin -- all of which are now on the market and positively impacting patients' lives."

Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. as Executive Vice President of Scientific Affairs from 2001 to 2005 before Vicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior to Vicuron, Dr. Stogniew served as Chief Scientific Officer at Next Pharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciences at MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and a B.S. in Pharmacy from the University of Maryland.

About Prestwick

Prestwick is currently managing a portfolio of pipeline product candidates being studied for CNS conditions with significant unmet needs, including Huntington's disease, Parkinson's disease, restless legs syndrome, schizophrenia, autism, Alzheimer's disease and sleep apnea.

Please go to http://www.prestwickpharma.com for more information.


'/>"/>
SOURCE Prestwick Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Traveling stem cell show continues state tour
2. AT&T - BellSouth merger: Revestiture continues
3. Madison biotech continues its climb
4. Brady continues growth through Asian acquisition
5. Transition continues to impact Third Wave financials
6. Line between big pharma, big biotech continues to blur
7. Wisconsin giant continues to dominate the health care IT market
8. API Software continues expansion
9. Third Wave continues molecular diagnostic focus with new CEO
10. Midwest Public-Sector Biotech Continues to Sizzle
11. Corona Optical Systems continues to excite investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Disappearing forests ... the lives of over 5.5 million people each year. Especially those living in larger ... startup Treepex - based in one of the most pollution-affected countries globally - decided ...
(Date:10/10/2017)... , ... October 10, 2017 , ... San Diego-based team ... its corporate rebranding initiative announced today. The bold new look is part of ... the company moves into a significant growth period. , It will also expand its ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... process optimization firm for the life sciences and healthcare industries, announces a presentation ... San Francisco. , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC ... announced that the United States Patent and Trademark Office ... broadly covers the linking of an iris image with ... transaction) and represents the company,s 45 th issued ... patent is very timely given the multi-modal biometric capabilities ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
Breaking Biology News(10 mins):